Clinical Overview
Paliperidone palmitate is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia and schizoaffective disorder in adults. It provides sustained medication delivery over one month, significantly improving medication adherence and reducing relapse rates in patients with chronic psychotic disorders.
Primary Clinical Applications
Invega Sustenna is indicated for schizophrenia and schizoaffective disorder treatment, offering monthly dosing that eliminates daily medication compliance issues. It is particularly valuable for patients with poor adherence to oral medications or frequent hospitalizations.
Mechanism and Clinical Benefits
As the palmitate ester of paliperidone, this formulation provides sustained release over 4 weeks through intramuscular injection. It maintains therapeutic levels while reducing the peaks and valleys associated with oral dosing, potentially improving tolerability and efficacy.
Administration Considerations
Requires specific injection technique and needle selection based on patient weight and injection site. The medication must be administered by healthcare professionals and requires initial oral tolerability testing in antipsychotic-naive patients.
Prescribing Information
Dosing & Administration
Schizophrenia Initiation:
- Day 1: 234 mg IM deltoid
- Day 8: 156 mg IM deltoid
- Monthly maintenance: 117 mg IM (deltoid or gluteal)
- Dose range: 39-234 mg monthly
Schizoaffective Disorder:
- Day 1: 234 mg IM deltoid
- Day 8: 156 mg IM deltoid
- Monthly maintenance: 117 mg IM
Renal Impairment:
- Mild (CrCl 50-80 mL/min): 156 mg day 1, 117 mg day 8, then 78 mg monthly
- Moderate-Severe: Not recommended
Indications
- Schizophrenia in adults
- Schizoaffective disorder as monotherapy or adjunct to mood stabilizers/antidepressants
Contraindications
- Known hypersensitivity to paliperidone, risperidone, or any component
Warnings & Precautions
- Boxed Warning: Increased mortality in elderly patients with dementia-related psychosis
- Cerebrovascular events: Increased risk in dementia patients
- Neuroleptic malignant syndrome: Discontinue immediately if suspected
- QT prolongation: Use caution in patients with cardiac risk factors
- Tardive dyskinesia: Risk increases with duration of treatment
Drug Interactions
- CNS depressants: Enhanced sedation
- QT-prolonging drugs: Additive QT effects
- Dopamine agonists: Antagonistic effects
- Carbamazepine: Increased paliperidone clearance
Adverse Reactions
Common (≥5%):
- Injection site reactions, somnolence, dizziness, akathisia
Metabolic:
- Weight gain, hyperglycemia, dyslipidemia
Special Populations
- Renal Impairment: Dose adjustment required for mild impairment
- Pregnancy: Use only if benefits outweigh risks
- Elderly: Increased mortality risk in dementia patients
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
